Summit and Sarepta to collaborate on muscular dystrophy drug

October 4, 2016 11:29 AM

4 0

Drugmaker Sarepta Therapeutics Inc has entered into an exclusive license agreement with Britain's Summit Therapeutics Plc to develop drugs to treat Duchenne muscular dystrophy (DMD), the companies said on Tuesday.

Summit will get $40 million up front and could receive up to $522 million in milestone payments, they said.

Also read: McKesson to Pay $150 Million for Failing to Report ‘Suspicious’ Drug Orders

Read more

To category page